- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04681248
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a intermediate-size Expanded Access Protocol (EAP). Patients who were receiving DKN-01 in a parent study at the time of completion of the parent study, and are, in the opinion of the Investigator and Sponsor, suitable candidates for continued study drug treatment are eligible for participation in the current EAP. In this EAP, previously treated patients will receive DKN-01 at the same dose and schedule as at the time of completion of the parent study. Furthermore, patients who received DKN-01 in combination in the parent study will continue to receive the same combination agent at the same dose and schedule in the EAP.
DKN-01 naïve patients, with advanced solid tumors not eligible for enrollment to a DKN-01 clinical study but whom, in the opinion of the treating oncologist, would potentially receive benefit from treatment with DKN-01 while it is an investigational drug may be eligible for enrollment in this EAP. Eligible DKN-01 naïve patients with Wnt activating mutations will receive DKN-01 as monotherapy, administered intravenously on Day 1 of each 21-day cycle at a dose of 600 mg, with a loading dose of 600 mg of DKN-01 administered on Day 15 of Cycle 1 only.
Study Type
Expanded Access Type
- Intermediate-size Population
Contacts and Locations
Study Contact
- Name: Leap Therapeutics, Inc.
- Phone Number: 617-714-0360
- Email: EarlyAccess@leaptx.com
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Available
- University of Alabama
-
Contact:
- Phone Number: 203-441-7938
- Email: DKN01.EAP@earlyaccesscare.com
-
-
California
-
Los Angeles, California, United States, 90025
- Available
- Cedars Sinai Medical Care Foundation
-
Contact:
- Phone Number: 203-441-7938
- Email: DKN01.EAP@earlyaccesscare.com
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Available
- Northwestern University
-
Contact:
- Phone Number: 203-441-7938
- Email: DKN01.EAP@earlyaccesscare.com
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53715
- Available
- University of Wisconsin
-
Contact:
- Phone Number: 203-441-7938
- Email: DKN01.EAP@earlyaccesscare.com
-
Milwaukee, Wisconsin, United States, 53226
- Available
- Medical College of Wisconsin
-
Contact:
- Phone Number: 203-441-7938
- Email: DKN01.EAP@earlyaccesscare.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Cytologically or histologically confirmed advanced solid tumors that are inoperable, locally advanced, metastatic, or recurrent, with no standard of care treatment options, and not eligible for enrollment to a DKN-01 clinical study, may be treated with DKN-01 in this study if in the opinion of the treating oncologist, would potentially receive benefit from treatment with DKN-01 while it is an investigational drug
- Prior documentation of a known Wnt activating mutation by a CLIA-accredited laboratory. Wnt activating mutations: CTNNB1, APC, AXIN1/2, RNF43, ZNRD3, RSPO2, RSPO3
- ECOG performance status (PS) of ≤ 2 (Medical Monitor's approval is needed for enrolling a patient with PS of 2).
Laboratory values:
- Total bilirubin ≤ 2.0 times upper limit of normal (ULN). Total bilirubin must be < 3 X ULN for patients with Gilbert's syndrome.
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 X ULN (if liver metastases are present, then ≤ 5 X ULN is allowed).
- Serum creatinine ≤ 1.5 X ULN.
- Neutrophil absolute count ≥ 1,500/mm3 (≥1.5 X 109/L).
- Platelet count ≥ 75,000/mm3 (≥100 X 109/L).
- Hemoglobin ≥ 9g/dL (transfusion within 30 days of screening is permitted).
Exclusion Criteria:
- Major surgery within 4 weeks of first dose of study drug.
- Toxicities (as a result of prior anticancer therapy) that have not recovered to baseline or stabilized, except for AEs not considered a likely safety risk (e.g., alopecia, neuropathy and specific laboratory abnormalities).
Any of the following cardiovascular risk factors:
- Pulmonary embolism within 28 days before first dose of study drug.
- Any history of acute myocardial infarction within 6 months before first dose of study drug.
- Uncontrolled hypertension that cannot be managed by standard anti-hypertension medications within 28 days before first dose of study drug.
- Severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy, including tuberculosis infection within 14 days of first dose of study drug.
- Active brain metastases. Patients are eligible if brain metastases are adequately treated, and patients are neurologically stable for at least 2 weeks prior to enrolment without the use of corticosteroids or are on a stable or decreasing dose of ≤ 10mg daily prednisone (or equivalent).
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Uterine Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Neoplasms, Complex and Mixed
- Sarcoma
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Stomach Neoplasms
- Adenocarcinoma
- Endometrial Neoplasms
- Carcinosarcoma
- Mixed Tumor, Mullerian
- Esophageal Neoplasms
- Uterine Neoplasms
Other Study ID Numbers
- DEK-DKK1-P206
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on DKN-01
-
Leap Therapeutics, Inc.CompletedMultiple Myeloma | Non-Small Cell Lung Cancer | Solid TumorsUnited States
-
Johannes Gutenberg University MainzLeap Therapeutics, Inc.Unknown
-
Leap Therapeutics, Inc.CompletedOvarian Cancer | Carcinosarcoma | Endometrial Cancer | Uterine CancerUnited States
-
Leap Therapeutics, Inc.Merck Sharp & Dohme LLCCompletedEsophageal Neoplasms | Gastric Adenocarcinoma | Adenocarcinoma of the Gastroesophageal Junction | Squamous Cell Carcinoma | Gastroesophageal CancerUnited States
-
NYU Langone HealthLeap Therapeutics, Inc.Terminated
-
Royal Marsden NHS Foundation TrustRecruitingMetastatic Gastric Cancer | Metastatic Esophageal CancerUnited Kingdom
-
Massachusetts General HospitalBristol-Myers Squibb; Leap Therapeutics, Inc.TerminatedBiliary Tract CancerUnited States
-
Leap Therapeutics, Inc.BeiGeneActive, not recruitingGastric Cancer | Gastric Adenocarcinoma | GastroEsophageal CancerUnited States, Korea, Republic of, Germany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Leap Therapeutics,...Recruiting
-
Leap Therapeutics, Inc.CompletedMultiple MyelomaUnited States